Trends in Pharmacological Sciences
ReviewMechanisms of inverse agonism at G-protein-coupled receptors
Section snippets
The spectrum of efficacy
Although a few years ago it was thought that drugs acting at GPCRs could be divided into two classes, agonists and antagonists, it now seems that for most GPCRs the compounds acting at these receptors exhibit a spectrum of efficacy from inverse agonism through neutral antagonism to agonism. In the same way as agonists can exhibit a spectrum of activity from low-intrinsic-activity partial agonists to full agonists so can inverse agonists. Full and partial inverse agonists have been described in
Physiological relevance of inverse agonism
Many drugs that had previously been considered to be antagonists have subsequently been shown to be inverse agonists in some assay systems. It is important to ask whether this matters in terms of drug effects in humans or animals. Many descriptions of inverse agonism rely on effects in recombinant systems but it is important to examine effects in native tissues. Acute administration of inverse agonists to native tissues might be expected to suppress the basal (agonist-independent) activity of a
Mechanisms of inverse agonism
Thus, inverse agonists might exert their effects either acutely or chronically. Understanding the mechanism of the effects of inverse agonists is important because it could provide new ways to design drugs of defined intrinsic activity. During activation of ionotropic receptors, these receptors undergo a series of allosteric transitions between different conformational states [16] so that inverse agonists presumably stabilize certain states of the receptor with different functional activities.
Stabilization of the R state of the receptor by inverse agonists at the expense of the R* state
One of the first tests of the proposal that inverse agonists stabilize the R state of the receptor at the expense of the R* receptor state was to use certain mutants of GPCRs that were thought to favour the R* state, the so-called constitutively active mutants [17]. If the R* state is favoured for these mutants and the inverse agonist binds preferentially to R over R*, it might be assumed that the affinity of the inverse agonist would be reduced by the mutation. However, this is a rather
Stabilization of the R state over the R*G state
One of the earliest descriptions of inverse agonism for GPCRs was for opiate receptors 25, 26. It was suggested that inverse agonists were switching the receptor between the RG and R states of the receptor. This depended on the sensitivity of the binding of inverse agonists to the effects of guanine nucleotides. Agonist affinity was decreased by GTP whereas inverse agonist affinity was increased and it was assumed that GTP was destabilizing the RG state. It was suggested that whereas agonists
Radiolabelled agonist and inverse agonist binding
It is important to consider the use of another tool for probing the mechanism of inverse agonism that is related to the effects of guanine nucleotides described above. This concerns the evaluation of inverse agonist affinity in competition studies versus radiolabelled agonist binding and versus radiolabelled inverse agonist binding (Box 3). If the extended ternary complex model holds for the system concerned, a radiolabelled agonist should label the R*G state with high affinity. A radiolabelled
Concluding remarks
Inverse agonism can be achieved by more than one mechanism. For some compounds there is evidence that inverse agonism is achieved by the stabilization of the R state of the receptor over the R* state. For other compounds there is no redistribution of the different affinity states of the receptor but the inverse-agonist–receptor complex is inactive. This suggests that different inverse agonists stabilize a receptor in different conformations with different functional consequences.
Chemical name
Acknowledgements
I thank David Hall and Sam Hoare for their insightful comments on this paper.
References (45)
An allosteric model for benzodiazepine receptor function
Biochem. Pharmacol.
(1983)Inverse, protean and ligand-selective agonism: matters of receptor conformation
FASEB J.
(2001)Inverse agonism at G protein coupled receptors: (patho)physiological relevance and implications for drug discovery
Br. J. Pharmacol.
(2000)- et al.
Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in Spodoptera frugiperda cells
J. Biol. Chem.
(1997) - et al.
Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors
Br. J. Pharmacol.
(1997) Constitutive activity and structural instability of the wild-type human H2 receptor
J. Neurochem.
(1998)The cubic ternary complex model 1. Model description
J. Theor. Biol.
(1996)Drug efficacy at guanine nucleotide binding regulatory protein linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand
Mol. Pharmacol.
(1992)- et al.
Mechanisms of agonism and inverse agonism at serotonin 5HT1A receptors
J. Neurochem.
(2000) Modulation of muscarinic cholinergic receptor affinity for antagonists in rat heart
J. Pharmacol. Exp. Ther.
(1984)
Dopamine receptors of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists
Mol. Pharmacol.
The ternary complex model
Mol. Pharmacol.
Effects of GTP on [3H]domperidone binding and its displacement in rat striatal homogenates
J. Recept. Res.
Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D2 dopamine receptor
J. Biol. Chem.
Dopamine D2 receptors selectively labelled by a benzamide neuroleptic [3H]YM-09151-2
Naunyn-Schmiedebergs Arch. Pharmacol.
Inverse agonism and the regulation of receptor number
Trends Pharmacol. Sci.
Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential
Fundam. Clin. Pharmacol.
Agonist independent regulation of constitutively active G protein coupled receptors
Trends Biochem. Sci.
Inverse agonism and neutral antagonism at α1a and α1b adrenergic receptor subtypes
Mol. Pharmacol.
Facilitation of constitutive α2A adrenoceptor activity by both single amino acid mutations (Thr373Lys) and Gαo protein
J. Pharmacol. Exp. Ther.
Inverse agonist activity of β-adrenergic agonists
Mol. Pharmacol.
Inverse agonism of histamine H2 antagonists accounts for up-regulation of spontaneously active histamine H2 receptors
Proc. Natl. Acad. Sci. USA
Cited by (116)
Ischemic stroke and traumatic brain injury: The role of the kallikrein-kinin system
2013, Progress in Neurobiology